Inflammatory Markers in Obstructive Sleep Apnea (OSA) Patients.

University of Crete

Status: Completed

Conditions: Obstructive Sleep Apnea of Adult

Treatments: Procedure: Venous blood collection for biomarkers measurements

Study type: Observational

Funder types: Other

Identifiers

NCT03070769

OSAINFL1

Details and patient eligibility

About

The aim of our study was to assess the levels of inflammatory biomarkers in a large sample of OSA patients and to investigate any correlation between these markers with clinical and polysomnographic (PSG) parameters.

Subjects undergone a PSG for OSA diagnosis were recruited. Patients with known comorbidities were excluded from the study. Included patients were grouped according to apnea-hypopnea index (AHI) as mild, moderate and severe. Patients with AHI < 5 served as control group. Demographic, PSG data, serum levels of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) were measured and compared between groups.

Full description

Systemic inflammation is important in obstructive sleep apnea (OSA) pathophysiology and its comorbidity. The objective of this study was to investigate how early biomarkers of inflammation may be altered in OSA patients. To complete this goal the investigators assessed the circulating levels of four inflammatory markers, hs-C-reactive protein (hs-CRP), Fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) in a representative population of consecutively enrolled, untreated and otherwise healthy subjects with a clinical suspicion of obstructive sleep apnea. A secondary objective was to investigate any correlation between these markers with clinical and polysomnographic (PSG) parameters of these subjects.Subjects who had undergone a PSG for OSA diagnosis were recruited. Patients with known comorbidities were excluded from the study. Included patients were grouped according to apnea-hypopnea index (AHI) as mild, moderate and severe. Patients with AHI < 5 served as control group. Demographic, PSG data, serum levels of hs-CRP, fibrinogen, ESR and UA were measured and compared between groups.

Enrollment: 1,053 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• newly diagnosed, untreated, and otherwise healthy obstructive sleep apnea (OSA) patients
• healthy subjects (without OSA)

Exclusion criteria

• refusal to participate,
• previous OSA diagnosis and treatment
• known comorbidities,
• pregnancy,
• history of narcolepsy or restless leg syndrome.
• Subjects younger than 18 years,
• Central sleep apnea syndrome (CSAS) diagnosed with PSG,

Trial design

1,053 participants in 2 patient groups

Control

Description:

Subjects without Obstructive sleep apnea (Apnea-hypopnea index-AHI<5). Venous blood collection for biomarkers measurements.

Treatment:

Procedure: Venous blood collection for biomarkers measurements

Obstructive sleep apnea (OSA) patients

Description:

Patients with Obstructive sleep apnea (AHI> or =5). Venous blood collection for biomarkers measurements.

Treatment:

Procedure: Venous blood collection for biomarkers measurements